UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients
High-dose chemo plus stem cell rescue offers hope for relapsed Wilms tumour
This clinical trial report evaluates outcomes for 78 children with relapsed or refractory Wilms tumour treated in the United Kingdom.
A UK trial found that a risk-stratified protocol with high-dose melphalan and stem cell rescue helped some children with relapsed Wilms tumo…
Exploratory RCT finds in situ vaccine plus PD-1 with immunoradiotherapy shows response in advanced hepatic malignancies
New Vaccine Combo Shrinks Liver Tumors Safely
An exploratory RCT of 18 patients with advanced hepatic malignancies compared in situ vaccine FOLactis plus PD-1 antibody combined with eith…
A new vaccine combo shrinks liver tumors safely without the severe side effects usually caused by strong cancer drugs.
Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients
New Drug Combo Helps Most Patients With Hard-to-Treat Lymphoma
This phase 1b multicenter clinical trial evaluated mitoxantrone hydrochloride liposome combined with cyclophosphamide, vincristine, and pred…
A new drug combo wrapped in fat bubbles helped 89% of patients with hard-to-treat lymphoma shrink tumors without causing deaths.
Case report: Low-intensity chemotherapy achieves remission in PMF transformed to MPAL
Single case report describes treatment for rare leukemia transformation in elderly patient
A case report describes a 75-year-old female with JAK2V617F-positive primary myelofibrosis that transformed to mixed phenotype acute leukemi…
A 75-year-old woman with rare leukemia transformation from blood disorder achieved remission after two cycles of low-intensity chemotherapy.
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma
Can adding a drug cocktail to radiation help keep early lymphoma from returning?
In a multicenter RCT with 150 patients with early-stage follicular lymphoma and 11.3-year median follow-up, involved-field radiotherapy plus…
Adding R-CVP drugs to radiation therapy helps early-stage lymphoma patients stay cancer-free longer, with mostly temporary side effects and …